首頁 › 乳癌 › 愛荷華 › Cedar Rapids
Cedar Rapids, IA 的 乳癌 臨床試驗
17 項針對 乳癌 的研究正在 Cedar Rapids（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
招募中1/2 期
- University of Iowa Hospitals and Clinics, Iowa City · 距離 25 英里
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
招募中1/2 期
- Local Institution - 0065, Iowa City · 距離 25 英里
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- University of Iowa, Iowa City · 距離 25 英里
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
招募中1 期
- University of Iowa Hospitals and Clinics, Iowa City · 距離 25 英里
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 距離 25 英里
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- University of Iowa, Iowa City · 距離 25 英里
Exercise Oncology Clinic Pilot Feasibility Trial
招募中
- University of Iowa Health Care, Iowa City · 距離 25 英里
Breast Cancer PSMA PET
招募中早期第 1 期
- University of Iowa Healthcare, Iowa City · 距離 25 英里
E-Mindfulness Approaches for Living After Breast Cancer
招募中3 期
- Saint Luke's Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 距離 25 英里
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- University of Iowa, Iowa City · 距離 25 英里
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
招募中4 期
- Iowa Holden Comprehensive Cancer Center, Iowa City · 距離 25 英里
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
招募中1 期
- University of Iowa Health Care, Iowa City · 距離 25 英里
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- Saint Luke's Hospital, Cedar Rapids
Quantitative MRI Assessment of Breast Cancer Therapy Response
招募中觀察性研究
- University of Iowa, Iowa City · 距離 25 英里
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- Physicians' Clinic of Iowa PC, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 距離 25 英里
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Iowa City · 距離 25 英里
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Cedar Rapids 的其他研究
- 非小細胞肺癌20 項研究
- 癌症（所有類型）16 項研究
- 急性髓系白血病16 項研究
- 多發性骨髓瘤15 項研究
- 肺癌14 項研究
- 大腸直腸癌13 項研究
- 頭頸部鱗狀細胞癌12 項研究
- 前列腺癌12 項研究
- 中風10 項研究
- 黑色素瘤10 項研究
- 子宮內膜癌9 項研究
- 血液癌症9 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。